

## Special Issue

# Vaccines and Vaccine Adjuvants for Infectious Diseases and Autoimmune Diseases

### Message from the Guest Editor

Vaccines are essential in eradicating or controlling many infectious diseases. In this context, several possible mechanisms (epitope spreading, bystander activation molecular mimicry, etc.) are postulated. In addition, microbial components are indispensable in several animal models of autoimmune diseases. Recent concerns in this area include the autoimmune manifestations associated with COVID-19 vaccines, although incidences of autoimmune diseases after other vaccinations were reported as well. At the same time, people living with autoimmune disease(s) need to take care of themselves to protect against various infections. Therefore, on this topic, we invite original and review articles covering the following three aspects: 1. Central theme: development of vaccines for infectious diseases or autoimmune diseases; 2. Exploration: how vaccines for infectious diseases might cause autoimmune diseases; 3. Accessories: vaccine adjuvants (natural and synthetic polymers, microbial and nonmicrobial components, their mode of action, and beneficial and adverse effects).

---

### Guest Editor

Prof. Dr. Kutty Selva Nandakumar

Department of Environmental and Biosciences, School of Business, Innovation and Sustainability (FIH), Halmstad University, Halmstad, Sweden

---

### Deadline for manuscript submissions

closed (31 May 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/143704](https://mdpi.com/si/143704)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).